Progress Report on the HOMED‐BP Study: Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure Study
Progress Report on the HOMED‐BP Study: Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure Study
复制标题
HOMED-BP 研究进展报告：基于电子血压装置测量的高血压客观治疗研究
DOI：
10.1081/ceh-120028548
复制
发表时间：
2004
影响因子：
12.3
通讯作者：
Y. Imai
中科院分区：
文献类型：
--
作者：
Yohei Aoki;K. Asayama;T. Ohkubo;Takuya Nishimura;M. Kikuya;H. Metoki;A. Hozawa;J. Hashimoto;M. Michimata;M. Matsubara;T. Araki;Y. Imai
基于电子血压测量的高血压客观治疗研究（HOMED BP研究）是日本首个采用前瞻性随机开放盲态终点（PROBE）设计的大规模干预试验，旨在根据在家自行测量的血压确定最佳目标血压（BP）水平，并确定最佳的降压药物初始疗程。通过互联网，通过主机将登记患者随机分配到更密集的降压组（家庭收缩压< 125 mmHg且舒张压< 80 mmHg）或不太密集的降压组（家庭收缩压/舒张压范围为134-125/84-80 mmHg）。三类初始降压方案对预后的不同影响，即，检查在日本最常用的钙拮抗剂（Ca-A）、血管紧张素转换酶抑制剂（ACE-I）或血管紧张素II受体拮抗剂（ARB）。三个方案也通过互联网随机分配到主机。2001年5月开始了一项试点研究。2002年3月，参与的医生人数为461人。截至2002年3月底，共招募了546名患者。其中，412例（202例男性和210例女性，年龄58.4 ± 10.2岁）接受了随机化。招募患者至2006年2月，并随访7年。
Hypertension Objective treatment based on Measurement by Electrical Devices of Blood Pressure Study (HOMED BP Study) is the first large‐scale intervention trial in Japan using a Prospective Randomized Open Blinded Endpoint (PROBE) design to determine an optimal target blood pressure (BP) level on the basis of self‐measured BP at home, and an optimal initial course of antihypertensive medication. The registered patients are randomized to either a more intensive BP‐lowering group (home systolic BP < 125 mmHg and diastolic < 80 mmHg) or a less intensive group (home systolic/diastolic BP within the range 134–125/84–80 mmHg) by host computer via the Internet. The differential effect of three classes of initial antihypertensive regimens on the prognosis, i.e., calcium antagonist (Ca‐A), angiotensin‐converting enzyme inhibitor (ACE‐I) or angiotensin II receptor antagonist (ARB), which are used most frequently in Japan, are examined. Three regimens are also randomly assigned to the host computer via the Internet. A pilot study was started in May 2001. In March 2002, the number of participating doctors was 461. At the end of March 2002, 546 patients were recruited. Of these, 412 (202 men and 210 women, aged 58.4 ± 10.2 y) were randomized. Patients will be recruited until February, 2006 and followed for 7 years.